Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Overview of attention for article published in Blood, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 15 news outlets
blogs: 2 blogs
twitter: 51 X users

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 78 Mendeley

So far, Altmetric has seen 24 news stories from 15 outlets.

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

BioSpace, 04 Nov 2025

– $45.9 million in total revenue, representing 21% growth over 2Q25 – – $32.0 million Revuforj® (revumenib) net revenue; total…

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

The Manila Times, 03 Nov 2025

- $45.9 million in total revenue, representing 21% growth over 2Q25 - - $32.0 million Revuforj® (revumenib) net revenue; total…

News story from Finanz Nachrichten on Monday 03 November 2025

Finanz Nachrichten, 03 Nov 2025

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Stockwatch, 03 Nov 2025

– $45.9 million in total revenue, representing 21% growth over 2Q25 – – $32.0 million Revuforj® (revumenib) net revenue; total…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 20 additional news stories.